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ABBREVIATIONS 
cADPR - cyclic adenosine diphosphate ribose 
cAMP - cyclic adenosine monophosphate 
CCK8 - cholecystokinin octapeptide 
cGMP - cyclic guanosine monophosphate 
CGRP - calcitonin gene-related peptide 
EDRF - endothelium derived relaxing factor 
HMG-CoA - 3-hydroxy-3-methyl-glutaryl coen2yme A 
i. v. - intravenous 
L-NAME - NG-nitro-L-arginine methyl ester 
NANC - nonadrenergic-noncholinergic 
NG - nitroglycerine 
NO - nitric oxide 
RIA - radioimmunoassay 
SDS/PAGE - sodium dodecyl sulfate/polyacrylamide gel electrophoresis 
SO - sphincter of Oddi 
TTX - tetrodotoxin 
VIP - vasoactive intestinal polypeptide 
wt - weight 
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1. INTRODUCTION 
Nitric oxide (NO) formed from L-arginine by a constitutive NO synthase in 
endothelial cells (1) was shown to play an important role in regulation of gastrointestinal 
blood flow (2, 3). From studies in vitro, NO has also been proposed as a mediator of 
nonadrenergic-noncholinergic (NANC) relaxation of the guinea pig stomach and ileum (4, 5), 
of the rat stomach, colon, duodenum and ileum (6, 7, 8, 9), of the canine ileo-cecal junction, 
ileum, duodenum and colon (10, 11, 12) and of human colon and internal anal sphincter (13). 
Pauletzki et al. (14) have shown that in the sphincter of Oddi (SO), L-arginine-NO pathways 
may play a major role in neural relaxation in the guinea pig. Nevertheless, regional 
differences in the excitatory and inhibitory innervations of the sphincter of Oddi of the latter 
species have also been well documented (IS). Subsequently, a series of experients from our 
department confirmed that the L-arginine-NO pathway played a crucial role in neural 
relaxation of the sphincter of Oddi of the rabbit with regional dominance on the ampullary 
part of the sphincter (16). 
Nitrergic mechanisms, however, are known to be highly susceptible to certain 
metabolic abnormalities e.g. hyperlipidaemia (17). It was not surprising therefore, that 
experimental hyperlipidaemia/atherosclerosis induced by dietary cholesterol overload 
significantly impaired NANC relaxation of the sphincter of Oddi of the rabbit (18). In the 
vasculature, functional defects have long been identified in endothelial cells in 
hypercholesterolaemia and atherosclerosis underlain by a decrease in the release/effect of 
endothelial NO (17). The reduced endothelium-dependent vasorelaxation due to 
hypercholesterolaemia/atherosclerosis has been proposed to result from a reduced formation 
and/or release of endothelium derived relaxing factor (EDRF) identified as NO. Nevertheless, 
the diminished nitrergic response may result from a more rapid inactivation of the NO 
released. Ohara et al. (19) have shown an increased superoxide anion production in 
hypercholesterolaemia and an improvement of EDRF-dependent relaxation by superoxide 
dismutase. Other mechanisms such as inactivation of NO by low-density lipoproteins was 
also mentioned (20). That the deficient sphincter of Oddi relaxing effect of amylnitrite, an 
exogenous non-enzymatic NO donor also restores with re-normalisation of serum cholesterol 
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level in clinical patients is in favour of changes at level of signal transduction in muscle cells. 
Thus, the primary aim of our work was to get an insight into mechanisms that are responsible 
for the impairment of nitrergic relaxation of the sphincter of Oddi produced by 
hypercholesterolaemia as well as to propose pharmacotherapeutic manoeuvres of possible 
benefit for the treatment of this particular type of biliary tract motility disorder. 
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2. GENERAL DESCRIPTION OF THE METHODS USED 
2.1. Ethics and experimental animals 
For studies on the sphincter of Oddi, we used New Zealand white rabbits. 
Experimental hypercholesterolaemia was induced in rabbits. The experiments performed in 
the present work conform to European Community guiding principles for the care and use of 
laboratory animals. The experimental protocol applied has been approved by the local ethical 
boards of Medical Universities of Szeged, Pecs and Debrecen, Hungary. 
2.2. Measurement of isometric tension 
Adult male New Zealand white rabbits weighing 3000-4000 g were stunned and 
exsanguinated. The duodenum with the sphincter of Oddi and the common bile duct were 
removed. Sphincter of Oddi muscle rings of approximately 4 mm length were prepared, 
cleaned of fat, adhering connective tissue and the underlying duodenum. Following removal 
of papilla Vateri, the muscle rings were mounted horizontally on two small L-shaped glass 
hooks one of which was connected to a force transducer (SG-02, Experimetria, Budapest, 
Hungary) attached to a six channel polygraph (R61 6CH, Mikromed, Budapest, Hungary) for 
measurement and recording of isometric tension. The experiments were carried out in an 
organ bath (5 ml) containing Krebs bicarbonate buffer (mM: NaCl 118.1, KC1 4.7, MgSC>4 
1.0, KH2P04 1.0, CaCl2 2.5, NaHCOs 25.0, glucose 11.1) which was maintained at 37°C and 
gassed continuously with 95% 0 2 and 5% C02. The pH of the solution was kept constant at 
7.4±0.05. The initial tension was set at 10 milliNewton (mN) and the sphincter of Oddi 
preparations were allowed to equilibrate for 60 min before the experiments were started 
during which period the sphincters developed characteristic 14-19 per min rhythmic 
contractions. Muscle rings with mechanical quiescence were excluded from the experiments. 
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Electrical field stimulation with 50 V square impulses of 0.1 ms duration was applied 
via two platinum wire electrodes positioned at each side of the muscle rings connected to an 
'Experimetria' ST 02 (Budapest, Hungary) two channel programmable stimulator. 
2.3. Determination of tissue cGMP and cAMP 
Tissue cyclic guanosine monophosphate (cGMP) and cyclic adenosine monophosphate 
(cAMP) content was determined as described Szilvassy et al. (21). In brief, the muscle rings 
were instantly frozen with the use of a precooled Wollenberger clamp and pulverized in liquid 
nitrogen. The samples were then homogenized in 6% (v/v) trichloroacetic acid of 10 times 
higher quantity than sample weight in a mortar previously kept at -70°C. After thawing, the 
samples were processed at 4 °C. Sedimentation at 15,000 g for 10 min by means of a Janetzki 
K-24 centrifuge (Leipzig, Germany) was followed by extraction of supernatants with 5 ml 
water-saturated ether in a Wortex extractor (MTA, Kutesz, type 5191, Budapest, Hungary) 
over 5 min. The ether fraction was eliminated, and the extraction was then five times 
repeated. After the fifth procedure, the samples were evaporated under nitrogen, and assayed 
for cAMP and cGMP contents by use of Amersham radioimmunoassay kits (Les Ulis, 
France). Values are expressed as pmol/mg wet tissue weight. 
2.4. Statistical analysis 
The isometric tension and nerve conduction velocity data expressed as means ± 
standard deviation (S.D.) were evaluated with analysis of variance (ANOVA) followed by a 
modified t-test according to Bonferroni's method. The blood chemistry data and the levels of 
both tissue cyclic nucleotides were evaluated by Student's t-test for unpaired data (22). 
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3. Further evidence for the nitrergic nature of NANC relaxation of the 
rabbit sphincter of Oddi. Cross tolerance with nitroglycerin. 
3.1. Concept 
Several studies have revealed that tolerance to organic nitroesters is accompanied by 
alterations in the cGMP system in both vascular (23) and gastrointestinal tissue (24). The 
production of cGMP is reduced in the tolerant tissue whereas its degradation is increased (25, 
26). Romanin & Kukovetz (27) have also shown that in tolerant tissue the soluble guanylate 
cyclase is partially desensitized. As this enzyme is believed to be a target for both exogenous 
and/or endogenous NO (1, 28), it is reasonable to speculate that tolerance to nitroglycerin 
(NG) may interfere with endogenous NO-dependent processes as well. Since this possible 
cross tolerance between nitroglycerin and endogenous NO had not been studied in the biliary 
tract, we commenced study to explore whether tolerance to NG influenced NANC relaxation 
in the ampullary part of the sphincter of Oddi of the rabbit in 1998 (29). 
3.2. Study design 
3.2.1. Isometric tension measurements 
Following the equilibration period of 60 minutes the muscle rings were exposed to 
increasing concentrations of cholecystokinin octapeptide (CCK8) added to the organ chamber 
in half-log increments in a cumulative manner. A maximum contractile response to CCK8 
was obtained, and the preparations were then washed repeatedly with Krebs solution until 
tension returned to previous baseline level. To study the effect of NG, the rings were 
precontracted by the ECso concentration of CCK8. After a stable half maximum contractile 
response to CCK8 was obtained, the preparations were exposed to cumulative increases in 
NG concentration in half-log increments. Following washout, 6 rings were exposed to 
275 pM NG for 1 h according to Silver et al (30) to induce in vitro tolerance to NG. The rings 
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were then extensively rinsed and transferred into naive tissue bath. The sphincter of Oddi 
preparations were then precontracted with the EC50 concentration of CCK8 and subsequently 
tested for relaxation to NG concentrations in half-log increments. These muscle rings 
exhibiting a significantly impaired relaxation in response to NG (see results) referred to as 
preparations 'tolerant' to NG. Another 6 rings were incubated with the solvent for NG in the 
same way. These preparations served as controls and underwent the same protocol. These 
preparations referred to as non tolerant ones. Following washout, the SO preparations (both 
tolerant and non tolerant) were subjected to electrical field stimulation. Stimulation with SO V 
square impulses of 0.1 ms duration was applied via two platinum wire electrodes positioned at 
each side of the muscle rings connected to an 'Experimetria' ST 02 (Budapest, Hungary) two 
channel programmable stimulator (16). Contractile responses of the muscle rings to two 
consecutive trains of impulses consisting of 3 and 10 stimuli (SO V, 0.1 ms and 20 Hz) 
divided by a 2 minute interstimulating interval, were studied. The muscle rings were then 
preincubated with phentolamine, oxprenolol and atropine (all 1 pM) for 20 min. and the field 
stimulation protocol was repeated. These drugs were added to block adrenoreceptors and 
muscarinic receptors (NANC solution'). Then N^nitro-L-arginine methyl ester (L-NAME), 
an inhibitor of NO synthase (31), at a concentration of 30 pM was added to the solution. The 
sphincters were subjected to the same field stimulation protocol after a 20 min. incubation 
with L-NAME. These procedures were followed by a successive incubation with 3 mM 
L-arginine (20 min.). The field stimulation protocol was repeated after L-arginine as well. 
Following extensive washout, the field stimulation protocol was repeated to test whether 
prodrug contractile responses could be reproduced. The muscle rings with altered spontaneous 
mechanical activity or exhibiting any significant increase or decrease in contractile responses 
to field stimulation (compared to control stimulations) were excluded from the study. 
Following the experiments, each muscle ring was subjected to histological examination by an 
unbiased histologist who confirmed that the SO specimens were not contaminated by 
adhering duodenal tissue. 
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3.2.2. Sampling for determination of tissue cyclic nucleotides 
Sampling for cAMP and cGMP determination was done (1) after the equilibration 
period in the absence of any pharmacological maneuvers (control), (2) after a 20 min. 
incubation with NANC' solution, (3) when maximum contraction was obtained in response to 
field stimulation using 10 stimuli, (4) when maximum relaxation was obtained in response to 
field stimulation (10 stimuli) in "NANC1 solution. The same sampling protocol was repeated 
with the 'tolerant' muscle rings. 
3.2.3. Drugs and chemicals 
N°-Nitro-L -arginine methyl ester, L-arginine hydrochloride, and tetrodotoxin (TTX) 
were obtained from Sigma Chemical Company (St Louis, USA). Phentolamine mesylate, 
oxprenolol hydrochloride and atropine sulphate were purchased from EGIS Chemicals 
(Budapest, Hungary). The compounds were dissolved in Krebs solution and added directly to 
the organ bath in a 50 pi volume. Nitroglycerin was purchased from Pohl-Boskamp GmbH 
(Hohenlockstedt, Germany). 
3.3. Results 
3.3.1. Effect of nitroglycerin on contractile activity stimulated by CCK8 in tolerant and 
non tolerant sphincter of Oddi muscle rings 
The maximum increase in peak contractions produced by CCK8 was not different between the 
'tolerant' and 'non tolerant' sphincters, with 29.9±5.8 and 28.3±5.2 mN (n=6), respectively. 
The sensitivity to CCK8 also was not different between the groups with ECso (-log M) values 
of 8.5±0.2 and 8.3±0,1, respectively. Preparations precontracted with ECso CCK8 which 
were exposed to a preceding incubation with 275 pM NG over 60 min ('tolerant'), exhibited a 
depressed relaxation response to NG relative to muscle rings preexposed to the vehicle of NG 
12 
('non tolerant1) (Fig.l/a). The EC50 concentration (-log M) values of NG were 7.4±0.2 and 
5.2±0.1 mN (p<0.01) on 'non tolerant' and 'tolerant' muscle rings, respectively. The 
concentration of NG producing nearly maximum relaxation in CCK8-precontracted 
'non tolerant' preparations, failed to attenuate contractions provoked by CCK8 in majority of 
the 'tolerant' rings (Fig.l/b). 
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Fig. 1/a. 
Fig. 1/b. 
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I • \ \ 
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Fig. 1. Tolerance to nitroglycerin (NG) in isolated rabbit sphincter of Oddi (SO) in vitro, (a) Relaxation 
responses of SO muscle rings precontracted with EC5 0 cholecystokinin octapeptidc (CCK8) to cumulative 
concentrations of NG. SO preparations were exposed to 275 p M NG ( • = tolerant) or vehicle (o= non-
tolerant) for lh, rinsed extensively and then resuspended in naive tissue baths. Following contraction with 
EC5 0 CCK8, smooth muscle relaxation to added cumulative concentrations of NG was quantified. Values 
are the means ± standard deviation (SD) obtained from experiments with six preparations in each group. An 
asterisk indicates a significant difference between values obtained with tolerant and non-tolerant muscle 
rings at P<0.05. (b) Original tracing showing the effect of NG (5x10" M) on contractile activity of isolated 
rabbit SO stimulated by EC5 0 CCK8 in tolerant (bottom) and non tolerant (top) preparations. The arrows 
indicate application of CCK8 or N G into the organ bath as well as the commencement of washout. 
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3.3.2. Effect of tolerance to nitroglycerin on NANC relaxation of the ampullary sphincter of Oddi 
Repetitive field stimulation evoked twitchlike contraction followed by relaxation in 
the ampullary SO in both non tolerant and tolerant preparations. The magnitude of 
contractions and relaxations was proportional to the number of stimuli (Fig 2/a and e). 
Combined application of 1 pM atropine, oxprenolol and phentolamine resulted in 
monophasic relaxations in response to field stimulation proportional to the duration of 
stimulation in non tolerant sphincters (Fig. 2/b) but not in tolerant ones (Fig. 2/f). In the 
presence and absence of these agents, responses elicited by electrical field stimulation were 
completely blocked by TTX (1 pM) and were therefore regarded as nerve responses (data not 
shown). Nevertheless, additional incubation with L-NAME (30 pM) reversed field 
stimulation-induced NANC relaxation in non tolerant muscle rings (Fig. 2/c) whereas the NO 
synthase inhibitor failed to modify stimulation-induced NANC contractions in the tolerant 
preparations (Fig 2/g). L-arginine (3 mM) completely reversed the inhibitory effect of 
L-NAME on NANC relaxation in the non tolerant tissue (Fig. 2/d) and it was without effect 
on field stimulation-induced contractions in the tolerant sphincters (Fig.2/h). 
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Fig. 2. 
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TOLERANT 
1 
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L-ARGININE d uuMÀmM mMiJWI_Uu b hhJaJMjumJU XjuIujua 10 mN 
1 minute 
Fig. 2. Original tracings indicating the effect of electrical FS on motility of isolated rabbit sphincter of Oddi 
(SO). Left tracings in each plot (short arrows) represent changes in isometric tension in response to three 
stimuli; right tracings (long arrows) indicate changes in tension produced by 10 stimuli (50 V, 20 Hz, 0.1 ms for 
each). The first row (a and e) shows results obtained in SO preparations in normal Krebs solution. The second 
row (b and f) indicates results in NANC solution (see methods). The third row (c and g) shows the effect of N°-
nitro-L-arginine methyl ester (L-NAME) at concentration of 30 pM on NANC responses to FS. The fourth row 
represents findings after additional incubation with L-arginine (3 mM). 
3.3.3. Effect of nitroglycerin tolerance on field stimulation-induced changes in tissue cAMP 
and cGMP content 
Tolerance to NG was without effect on tissue content of both cyclic nucleotides 
measured (Fig. 3/a and b). Nevertheless, NANC cAMP values in the tolerant muscle rings 
were lower with a border-line significance (Fig. 3/a). Electrical field stimulation (20 Hz, 50 
V, 10 stimuli) increased tissue cAMP and cGMP content in non tolerant preparations either 
untreated (Krebs solution) or exposed to NANC solution. Field stimulation failed to increase 
the level of either cyclic nucleotide in tolerant tissue (Fig. 3/a and b). 
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Fig. 3/a. 
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Fig. 3. Effect of electrical FS on tissue cAMP (a) and cGMP (b) content in isolated SO muscle rings of the rabbit. 
Open columns: muscle rings incubated in Krebs solution; hatched columns: preparations incubated with 
phentolamine. oxprenolol and atropine (all 1 pM. NANC solution); grey columns: muscle rings made tolerant to the 
relaxing effect of nitroglycerin (NG) by a preceding exposure to 275 pM NG (followed by washout) over lh (NG-
tolerant) incubated by Krebs solution; solid columns: NG-tolerant preparations incubated by NANC solution. The 
data are the means ± SD obtained in six preparations in each group. An asterisk represents differences within the 
samples in the 'non-stimulated' group at P<0.05. A plus signifies significant difference between corresponding 
values obtained from non-stimulated and stimulated preparations at P<0.05. 
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4. Impairment of neural relaxation of the rabbit sphincter of Oddi by 
hypercholesterolemia. The role of farnesylation. 
4.1. Background 
We have shown that hypercholesterolaemia/atherosclerosis impairs relaxation function 
of the sphincter of Oddi in both experimental animals and clinical patients (18, 32). Moreover, 
the relaxant effect of exogenous non-enzymatic NO donors on the sphincter of Oddi also has 
been found impaired in hypercholesterolaemia (18). Since dietary hypercholesterolaemia may 
impair both the release and effect of NO through a deficiency in G-protein coupling at least in 
part due to a reduced synthesis of farnesyl or geranylgeranyl products (17), we sought 
whether farnesol supplementation elicited a partial recovery of nitrergic relaxation of the 
sphincter of Oddi preparations from hypercholesterolaemic rabbits in vitro. 
4.2. Study design 
4.2.1. Experimental groups 
The study was carried out with six experimental groups (with 11 animals in each). 
Group 1: normal animals treated with the solvent for farnesol two times a day over three days; 
Group 2: normal animals treated with farnesol (30 pmol/kg body weight) two times a day 
over three days; Group 3: hyperlipidaemic rabbits (1.5 % dietary cholesterol load over 8 
weeks) treated with the solvent for farnesol; Group 4: hyperlipidaemic rabbits treated with 
farnesol. Each group was divided into two subgroups: six preparations from six animals were 
used for isometric tension measurements, whereas five muscle rings from five rabbits were 
used for determination of tissue cGMP by means of radioimmunoassay. 
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4.2.2. Drugs and chemicals 
All drugs and chemicals used in this study were purchased from Sigma (St Louis, Mo). 
Atropine and guanethidine were freshly dissolved in Krebs solution and added to the organ 
baths in 50 pi volume. Farnesol (3,7,ll-trimethyl-2,2,10-dodecatrien-l-ol, mixed isomers) 
was diluted with 0.5 ml/kg body weight propylene glycol, therefore, propylene glycol was 
referred to as the solvent for farnesol. 
4.2.3. Protocol for tension measurement 
Biliary sphincter of Oddi muscle rings of approximately 6 mm length from adult male 
New Zealand white rabbits weighing from 3500-4000 g were prepared. The papilla Vateri 
was eliminated and the ampullary part of the muscle rings of approximately 3 mm length were 
mounted horizontally on two small L-shaped glass hooks of which one was connected to a 
force transducer attached to the polygraph. The experiments were carried out in an organ bath 
(5 ml) containing Krebs bicarbonate buffer as described (2.2.). Atropine (1 pM) and 
guanethidine (4 pM) were continuously present (NANC solution). Changes in isometric 
tension in response to two consecutive trains of impulses of electrical field stimulation (50 V, 
0.1 ms, 20 Hz and 40 stimuli) were then studied. 
4.3. Results 
The cholesterol-enriched diet increased serum cholesterol to 22.6±3.8 vs pre-diet 
1.4±0.3 mmol/1. In rabbits fed normal chow, serum cholesterol did not change during the 
same period and farnesol was without effect on serum cholesterol level. 
Field stimulation-induced monophasic NANC relaxation in sphincter of Oddi muscle 
rings from normal rabbits treated with the solvent for farnesol. Treatment with farnesol (30 
pmol/kg body weight) did not modify this response (not shown). Preparations from the 
solvent-treated hypercholesterolaemic rabbits responded with NANC contractions to field 
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Fig. 5. 
R e s t i n g A f t e r F S 
Fig. 5. Changes in cGMP content of sphincter of Oddi muscle rings in response to electrical field stimulation 
(0.1 ms, 50 V, 20 Hz, 40 stimuli). Open bars: rings from solvent-treated normal animals; vertical line bars: 
solvent-treated atherosclerotic; hatched bars: farnesol-treated normal; cross-hatched bars: atherosclerotic, 
farnesol-treated. Data are means ± SD obtained with five rings from five animals. *: atherosclerotic vs. normal 
atP<0.05; #: stimulated vs. resting at P<0.05. 
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5. Impairment of neural relaxation of the rabbit sphincter of Oddi by 
3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibition. 
5.1. Background 
As seen above, farnesol supplementation improves NANC relaxation of the sphincter 
of Oddi from animals with experimental hypercholesterolaemia. This is in agreement with 
results by Roullet et al. (33, 34) that farnesyl analogues re-normalize vascular tone 
deteriorated by either hypercholesterolaemia or inhibition of HMG-CoA reductase, a key 
enzyme in the mevalonate pathway independent of plasma cholesterol levels. Therefore, in a 
series of experiments we studied if pharmacological inhibition of HMG-CoA reductase by 
chronic administration of lovastatin decreased the NANC relaxation response in sphincters 
from normal animals and as to whether this could be masked by farnesol supplementation. 
5.2. Study design 
5.2.1. Experimental groups 
Sphincter of Oddi muscle rings were prepared from groups of adult male New-Zealand 
white rabbits (3000-3500 g) as follows: untreated animals Group 1, and from those treated with 
lovastatin (5 mg/kg/day intragastrically, over 5 days) Group 2, or farnesol (1 mg/kg 
intravenously, twice a day for 5 days) Group 3, and from those given lovastatin + farnesol over 
5 days Group 4. Each group consisted of 23 preparations from 23 animals, six of which were 
used for measurement of isometric tension; five rings entered radioimmunoassay studies for 
determination of baseline cAMP and cGMP, eight rings were used for determination of tissue 
NO and four rings per group served for Western blot analysis of the membrane-associated G-
protein subunit Gsa Two additional groups were instituted to test the effect of the solvent for 
farnesol and the placebo for lovastatin (four preparations for isometric tension measurements, 
three for cyclic nucleotide- and four for NO determinations per group). To reduce the number 
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of experimental animals, field stimulation-induced changes in tissue cyclic nucleotide 
concentration were determined from the same preparations as those used for isometric tension 
measurements. 
5.2.2. Methods 
The measurement of isometric tension, the determination of cyclic nucleotide content 
in samples from isolated rabbit sphincter of Oddi and the serum cholesterol level was 
described (35). 
5.2.3. Membrane preparations and Western blot analysis 
Sphincter of Oddi muscle rings were homogenized in ice-cold 50 mM Tris/HCl (pH 
7.4 at 25 °C) containing 10 pg/ml soybean trypsin inhibitor, 5 pg/ml leupeptin, 200 pg/ml 
bacitracin, 2 mM EDTA and 100 pM phenyl-methyl-sulfonyl fluoride to prevent proteolysis. 
The supernatant fraction resulting from centrifiigation with 600 X g for 10 min. was re-
centrifuged at 30 000 X g for 15 min. at 4 °C. The pellet was re-homogenized in fresh buffer 
and re-centrifuged. The final pellet was re-suspended in ice-cold assay buffer (50 mM 
Tris/HCl, 5 mM MgCk, pH 7.4 at 25 °C ), and protein content was determined by Lowry's 
method using bovine serum albumin as a standard. Membrane preparations were maintained 
at -80 °C for up to two weeks until utilized in assays. Sodium dodecyl sulfate/polyacrylamide 
gel electrophoresis (SDS/PAGE) and Western blotting were performed using the procedure 
previously described by Miyamoto et al (36). In brief, membrane suspensions were dissolved 
in an equal volume of sample buffer containing 62.5 mM Tris,/HCl (pH 6.8), 10 % glycerol, 2 
% SDS, 5 % mercaptoethanol and 0,0025% bromophenol blue and boiled for 5 min. before 
application to the gel (7.5 pg protein per lane). After electrophoresis (40 mA for 100 min.), 
the gels were soaked for 20 min. in transfer buffer (25 mM Tris, 192 mM glycine, and 20 % 
methanol). Proteins were transferred from the gel to pre-soaked nitrocellulose membranes at 
180 mA over 90 min. The membranes were incubated for 2 h in 0.01 M Tris/HCl, (pH 
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7.4)/0.9% NaCl containing 3 % bovine serum albumin. Immunodetection was carried out by 
incubating the membrane with specific sheep antiserum recognizing Gsa diluted 1:2000 with 
the above buffer overnight at room temperature. The membranes were washed 5 times over 30 
min. Membranes were then incubated for 2 h at room temperature with horseradish 
peroxidase-conjugated goat anti-sheep IgG diluted 1:1000 with the above buffer. The 
antibody bound to nitrocellulose membrane was detected by the chromogenic substrate 4-
chloro-l-naphtol. Immunoreactivity was also detected with the enhanced chemiluminescence 
Western Blot Detection System followed by exposure to Hyperfilm-enhanced 
chemiluminescence. Immunolabelled G proteins and the intensity of the specific bands were 
assayed by Soft Laser Scanning Densitometer (Biomed Instruments, USA). 
5.2.4. Tissue NO determination by means of electron spin resonance 
Nitric oxide content of freshly minced sphincter of Oddi tissue was measured using 
electron spin resonance spectroscopy after spin trapping with 55 mmol/L N-methyl-
glucosamine-dithiocarbamate as described in details elsewhere. NO content was expressed as 
arbitrary units/mg tissue (37,38,39). 
5.2.5. NANC neurotransmitter release studies 
Calcitonin gene-related peptide (CGRP), concentrations were determined from 200 ml 
samples of organ fluid of the preparations by means of radioimmunoassay methods developed 
in our laboratories as described (40,41). For radioimmunoassay determination of vasoactive 
intestinal polypeptide (VIP) we used commercial radioimmunoassay kits (Amersham, Les 
Ulis, France). Sampling was done prior to (resting values) and immediately after field 
stimulation (at maximum contraction/relaxation). 
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5.2.6. Sampling for cyclic nucleotide and NO determination 
The muscle rings used for isometric tension measurements were used for 
radioimmunoassay studies as well, to determine field stimulation-induced changes in tissue 
cyclic nucleotide levels. Sampling was done so that the whole preparation exhibiting 
contraction/relaxation in response to field stimulation was placed in liquid nitrogen in 2 s 
subsequent to the maximum contractile response. For control to these series of rings served 
those, which had not been subjected to field stimulation (resting values). The same sampling 
scheme was used for tissue NO measurement. 
5.2.7. Drugs and chemicals 
Beyond radioimmunoassay kits, all drugs and chemicals used in this study were 
purchased from Sigma (St. Louis, Mo) except lovastatin and its placebo (MEVACOR, Merck-
Sharp & Dohme Hungaria Kit., Budapest, Hungary). Atropine and guanethidine were freshly 
dissolved in Krebs solution and added to the organ baths in 50 pi volume. Farnesol was 
diluted with 0.5 ml/kg body weight propylene glycol, therefore, propylene glycol was referred 
to as the solvent for farnesol. 
5.2.8. Statistical analysis 
The data representing changes in isometric tension and neuropeptide release expressed 
as means±standard deviation (S.D.) were evaluated by means of analysis of variance followed 
by a modified Student's t test for multiple comparisons according to Bonferroni's method. 
Changes in tissue cyclic nucleotide and NO contents were evaluated by means of Student's t 
test. Changes were considered statistically significant at P values smaller than 0.05. 
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5.3. Results 
5.3.1. Isometric tension 
The NANC relaxation response was converted to contraction in animals treated with 
lovastatin. Lovastatin-farnesol combination restored the normal NANC relaxation response. 
Farnesol was without effect on NANC relaxation by itself (Fig. 6.). The NANC relaxation 
was not modified by the placebo for lovastatin or the solvent for farnesol. 
Fig. 6. 
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Fig. 6. Changes in isometric tension induced by electrical field stimulation (40 stimuli 50 V, 0.1 ms and 20 Hz) 
in sphincter of Oddi preparations in vitro. The data are expressed as means±S.D. obtained with 6 preparations in 
each group. Positive values indicate contraction, negative values denote relaxation. The original tracings in the 
upper part of the figure represent characteristic responses to field stimulation in each particular group. The 
arrows show commencement of field stimulation. 
5.3.2. Tissue NO content 
In tissue samples of the sphincter Oddi, neither lovastatin nor farnesol or their 
combination influenced either baseline or post-stimulation intensity of specific spectra of NO-
L-N-methyl-glucosamine-dithiocarbamate complex assessed by electron spin resonance as 
compared to those from the untreated animals (Fig. 7/a). 
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5.3.3. Changes in cyclic nucleotides 
Field stimulation-induced NANC relaxation was accompanied by a significant 
increase in both cGMP and cAMP in preparations from the untreated animals. In muscle rings 
obtained from the lovastatin-treated group, the increase in cGMP in response to field 
stimulation was much lower than that seen in sphincters from the untreated rabbits. 
Interestingly, field stimulation failed to increase cAMP in the lovastatin-treated group. 
Farnesol-lovastatin combination yielded complete restoration of the increase in both cyclic 
nucleotides in response to field stimulation (Fig. 7/b and c). Farnesol / its solvent or the 
placebo for lovastatin was without effect. 
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Fig. 7. Changes in tissue nitric oxide (a) cGMP (b) and cAMP (c) content of sphincter of Oddi muscle 
rings in response to electrical field stimulation (0.1 ms, 50 V, 20 Hz, 40 stimuli). Open bars: rings from 
untreated animals; vertical line bars: lovastatin-treated animals; hatched bars: farnesol-treated; cross-
hatched bars: lovastatin+ farnesol-treated. Data are means±S.D. obtained with six rings from six animals. 
*:lovastatin vs untreated at P<0.05; #: stimulated vs resting at P<0.05. 
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5.3.4. NANC neurotransmitter release studies 
Field stimulation induced a significant increase in CGRP and VIP concentration in 
organ fluid of the preparations as determined by means of radioimmunoassay. This was not 
modified by any of the treatments applied (Fig. 8/a and b). 
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Fig. 8. Changes in calcitonin gene-related peptide (CGRP. a) and vasoactive intestinal polypeptide (VIP. b) 
release from isolated sphincter of Oddi muscle rings in response to electrical field stimulation (0.1 ms, 50 V, 20 
Hz, 40 stimuli). Open bars: rings from untreated animals; vertical line bars: lovastatin-treated animals; hatched 
bars: farnesol-treated ; cross-hatched bars: lovastatin + farnesol-treated. Data are means±S.D. obtained with six 
rings from six animals. *:lovastatin vs untreated at P<0.05; #: stimulated vs resting at P<0.05. 
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5.3.5. Membrane composition of Gsaprotein in the sphincter of Oddi 
To estimate the effect of HMG-CoA inhibition on membrane particulation of G-
proteins in the sphincter of Oddi, quantification of Gsa protein, a representative of the 
membrane bound G-protein complex was done by immunodetection using specific Gs« 
antibody. The Gsa antiserum recognized a 57 kDa band, the density of which substantially 
decreased in membrane preparations from sphincter from animals treated with lovastatin (Fig. 
9). Farnesol supplementation revealed re-normalization of Gs« density in muscle from the 
lovastatin-treated group. Farnesol was without effect (Fig. 9). 
Fig. 9. 
Fig.9. Western blot analysis of Gsoc subunit in rabbit sphincter of Oddi membranes. 7.5 pg protein was loaded 
per lane. A representative gel obtained with preparations from untreated (open bars), lovastatin-treated (vertical 
line bars), famesol-treated (hatched bars) and lovastatin + famesol-treated (cross-hatched bars) animals is shown 
in the inset at the top of each corresponding bar. Densitometric results are expressed as a percent of density seen 
with preparations from untreated rabbits. Data are means±S.D. obtained with four preparations from four 
animals. *:treated vs untreated at P<0.05. 
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5.3.6. Serum cholesterol level 
Serum total cholesterol level of 2.1±0.3 mmol/1 decreased by 1.6±0.2 and 1.5±0.1 
mmol/1 (p<0.01 for both) by lovastatin and lovastatin + farnesol, respectively. Farnesol, the 
solvent for farnesol or the placebo for lovastatin were without effect. 
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6. DISCUSSION 
These results confirm previous findings that the L-arginine-NO pathway is involved in 
the NANC relaxation of the ampullary part of the rabbit sphincter of Oddi (16). Assay of 
tissue cAMP and cGMP has revealed that nerve stimulation increases the content of both 
cyclic nucleotides irrespective of either contraction (untreated sphincters) or relaxation 
(NANC medium) is the physiologic response. The results also indicate that the highly 
reproducible NANC relaxation in the ampullary rabbit sphincter of Oddi provoked by a 
standardized field stimulation protocol (16) is completely lost when tolerance to the smooth 
muscle relaxant effect of NG develops. Moreover, in the tolerant sphincter preparations, field 
stimulation failed to elicit any increase in the tissue level of either cAMP or cGMP. 
The nitrovasodilators are commonly used in the treatment of several diseases 
especially based on cardiovascular indications including ischaemic heart diseases, congestive 
heart failure and peripheral vascular diseases. Nevertheless, these drugs are often prescribed 
for non-cardiovascular patients, such as patients suffering from airway diseases, open-angle 
glaucoma, disturbed penile erection, achalasia, and, most frequently for the treatment of SO 
dyskinesis (28). The therapeutic benefit of these drugs is mainly based on their ability to relax 
smooth muscle. The mechanism of action is not yet fully understood, but it is strongly 
suggested that each nitrovasodilator must be considered as prodrug, which requires 
decomposition to pharmacologically active principle (42, 43) identified as NO (44). The 
mechanism of tolerance to organic nitroesters has not been clarified, although different 
hypotheses have been advanced, such as (i) tolerance caused by pharmacokinetic factors 
and/or (ii) the development of tolerance has been suggested to be due to oxydation of critical 
sulfhydryl groups in the receptor, thus converting the nitrate receptor to a low affinity state 
(26) and (iii) several studies have also been devoted to the question if tolerance to NG is 
accompanied by alterations in the formation and/or breakdown of cGMP. 
The intracellular messenger cGMP is considered an important mediator of smooth 
muscle relaxation induced by NG. Keith et al. (24) have found an inhibition of NG-induced 
cGMP generation in rat aortic strips obtained from rats made tolerant to the vasodilator effect 
of NG by the administration of 300 mg/kg body weight NG twice daily over three days. The 
relaxant response to the membrane-penetrating cGMP analogue 8-bromo-cyclic GMP was, 
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however, not altered in the tolerant tissue, indicating that the intracellular action of cGMP, 
once it is formed, is not impaired. Further studies revealed that the reduced cGMP response to 
NG in tolerant tissue was associated with a marked decrease in the activity of the cGMP 
generating enzyme guanylate cyclase. The activity of the cGMP hydrolysing cGMP 
phosphodiesterase, however, was found slightly elevated (25). By reason of these findings, it 
seems possible that the development of tolerance to NG involves a cross tolerance to the 
effect of other exogenous and endogenous NO donors that stimulate guanylate cyclase as 
well. This might at least in part be responsible for the failure of field stimulation to increase 
cGMP in the tolerant sphincter preparations with an impairment of the NANC relaxation. 
However, some authors argue against the concept of desensitisation of soluble guanylate 
cyclase in the state of tolerance to NG (45). Interestingly, field stimulation-induced increase 
in tissue cAMP was also abolished in the 'tolerant' preparations. Field stimulation is a 
commonly used convenient method to excite neurons in various tissue preparations but 
evaluation of both motor and biochemical responses after such a train of electrical impulses 
are complex (46) as field stimulation stimulates all kinds of neurons in the preparation and 
only the overall response induced by stimulation of diverse population of neurons can be 
observed. As the sphincter of Oddi is densely innervated with NANC neurons containing 
vasoactive intestinal polypeptide, peptide histidine-isoleucine, neuropeptide Y, calcitonine 
gene-related peptide galanin, somatostatin, substance P, enkephalin, bombesin (47, 48), and 
NO (49), it is not easy to interpret data obtained by the field stimulation method. 
The involvement of NO in NANC relaxation of the rabbit SO based on the field 
stimulation method has been discussed elsewhere (16). Nevertheless, besides NO, VIP is 
considered another putative mediator of NANC relaxation in many regions of the 
gastrointestinal tract that directly relaxes the smooth muscle cells with a concomitant increase 
in intracellular cAMP level (50). NO has been shown to enhance the release of VIP in rat 
colon (51) and the concept of such an interplay between the two NANC relaxants in the SO 
also seems to be indirectly supported by our present results. Theoretically but not exclusively 
NO may act to release VIP by a cGMP-dependent pathway. The possibility for cGMP-
regulated neurotransmitter release comes from the exigence that cGMP stimulates the 
formation of cyclic ADP ribose (cADPR), a put^iyp endogenous ligand for the ryanodyne-
sensitive intracellular calcium release channels ip qpurons. Thus, cGMP-dependent formation 
i • » 
of cADPR may regulate neurotransmitter release by modulating intracellular calcium 
handling (52). On the other hand, VIP also can stimulate the release of NO in both neurons 
and muscle cells. In addition, NO produced in muscle cells can act as a 'retrograde messenger' 
to release VIP from nerve terminals (51). Alternatively, NO released from nerve terminals can 
enhance VIP release presynaptically and relax smooth muscle postsynaptically. The effects of 
NO at least in part are mediated by cGMP (53) wheres the release of VIP results in an 
increase in cAMP (50). It is therefore not surprising that both cAMP and cGMP were 
significantly increased by field stimulation in the non tolerant tissue. Nevertheless, the lack of 
effect of the same field stimulation protocol on either second messenger in the tolerant tissue 
with a significant impairment of NANC relaxation of the 'tolerant' muscle rings suggest a 
putative primary effect of cGMP in the synergism of cAMP and cGMP to produce relaxation 
in the rabbit sphincter of Oddi. 
Our present results strongly suggest that when the formation of cGMP is inhibited by 
the development of cross tolerance between NG and endogenous NO (54) the production of 
cAMP (either VIP-dependent or VIP-independent) is also blocked in the ampullary sphincter 
preparations, therefore the synergistic smooth muscle relaxation attained by cAMP and cGMP 
is significantly attenuated. Thus, we conclude that these results together with previous 
findings call attention to the potential risk of attenuation of endogenous cGMP-dependent 
relaxation mechanisms in the state of nitrate tolerance. Considering that the most important 
endogenous cardioprotective mechanism i.e. ischaemic preconditioning (54, 55) was also 
found to be attenuated in rabbits with vascular tolerance to NG in vivo, we think that there is 
an emergency to find appropriate, clinically utilizable therapeutic regimens to reverse 
tolerance to NG and/or to preserve endogenous NO-dependent processes in patients 
maintained on prolonged nitrate therapy of whatever indication. 
Our further results show that either hypercholesterolaemia or the 5-day treatment with 
lovastatin, a prototype of HMG-CoA inhibitors impairs neurogenic relaxation of the rabbit 
sphincter of Oddi, a mechanism shown to be nitrergic in nature (16). In fact, the relaxation 
response was converted to contraction in preparations from either hypercholesterolaemic or 
the lovastatin-treated animals similar to that seen after NO synthase inhibition (16). However, 
the present electron spin resonance studies reveal that lovastatin is without effect on NO 
synthesis since neither baseline nor post-stimulation tissue NO levels differed from those 
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observed in muscle rings from untreated animals. Interestingly, the cGMP-increase in 
response to field stimulation was significantly lower in preparations from the lovastatin-
treated animals than that in the untreated group, with loss of the stimulation-induced cAMP-
increase after lovastatin. Treatment with farnesol attained a complete restoration of both 
neural relaxation and the cyclic nucleotide responses deteriorated by either 
hypercholesterolaemia or treatment with lovastatin. 
It is widely accepted that NO, through cGMP synthesis, induces a sequence of protein 
phosphorylation that leads to smooth muscle relaxation (1). The present results similar to that 
previously observed show that nitrergic relaxation of the rabbit sphincter of Oddi is 
accompanied by an increase in both cGMP and cAMP concentration (56). Theoretically, an 
increase in tissue cAMP concentration secondary to cGMP-increase might result from an 
inhibition of cAMP metabolism through inhibition of the enzyme type m (cGMP-inhibited 
cyclic nucleotide phosphodiesterase:PDE3) phosphodiesterase (57, 58). However, the 
simultaneous increase in tissue cGMP and cAMP concentration in response to field 
stimulation can better be attributed to the co-release of NO and VIP (51) the latter of which is 
known to cause activation of specific membrane receptors coupled to a G-protein complex for 
stimulation of adenylate cyclase and to increase cAMP (59, 60). Notwithstanding, cAMP may 
increase in response to field stimulation due to adenylate cyclase stimulation by 
neurotransmitters released from intrinsic or sensory nerve terminals of the sphincter of Oddi 
other than VIP such as CGRP (47, 61). Moreover, in addition to its smooth muscle relaxing 
effect, NO has been proposed to stimulate the release of VIP (and perhaps other cAMP 
elevating agents) from enteric nerve terminals through presynaptic mechanisms (62). VIP or 
CGRP once released, facilitate further NO synthesis/release through cAMP-dependent 
pathways, thus, an interplay between NO and these NANC peptides underlie the increase in 
cGMP and cAMP in the sphincter of Oddi. Our present results are in good agreement with 
these observations, since the field stimulation-induced NANC relaxation was accompanied by 
a significant increase in NO, CGRP and VIP with an ensuing increase in both cAMP and 
cGMP. 
The major original finding of our work is that a 5-day treatment with the HMG-CoA 
reductase inhibitor lovastatin similar to dietary hypercholesterolaemia (18) abolished the NANC 
relaxation phenomenon at least under our experimental conditions. In the vasculature, functional 
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defects have long been indentified in endothelial cells in hypercholesterolemia underlain by a 
deficiency in the release/some of the effects of NO both of which requiring the integrity of 
several G-protein effector systems (17). To fulfil their biological function, G-proteins must 
undergo a post-translation modification with farnesyl or geranylgeranyl moieties that enable 
them to associate with the membrane. The availability of these moieties, however, is reduced by 
both dietary hypercholesterolaemia (63) and as a result of HMG-CoA reductase inhibition. 
Similarly, farnesyl analogues have been found to re-normalize vascular tone deteriorated 
by either hypercholesterolaemia or inhibition of HMG-CoA reductase, a key enzyme in the 
mevalonate pathway independent of plasma cholesterol levels (33, 34). Moreover, the rapid 
pacing-induced ischaemic preconditioning phenomenon of the isolated working rat heart, another 
NO-dependent process (64) has been found to be similarly deteriorated by both experimental 
hypercholesterolaemia and HMG-CoA reductase inhibitor treatment (65). 
We therefore considered possible that a 5-day treatment with the HMG-CoA reductase 
inhibitor lovastatin influenced nitrergic relaxation in the gastrointestinal tract in a similar way, 
resulting in a deficiency of both the release and effect of NO. The present results only partially 
support this assumption since the release of neither NO nor that of the two relaxant peptides was 
attenuated by lovastatin treatment. However, possibly due to its G-protein dependence, no 
cAMP- increase was seen in sphincters from the lovastatin-treated group in response to field 
stimulation, whereas the G-protein-independent cGMP formation was only partially impaired. 
The relative deficiency in cGMP formation after lovastatin may reflect the possible cAMP-
dependent releasing effect of VIP and CGRP on NO. This latter mechanism, however, is not 
evident from our results, possibly due to the semi-quantitative nature of the electron spin 
resonance technique used for tissue NO determination, since approximately the same NO levels 
were seen with or without lovastatin. Furthermore, the smooth muscle relaxing effect of cGMP 
has been shown to involve a G-protein-dependent activation of potassium channels that 
contributes to G-protein-independent relaxation pathways (66) (Fig. 10.). Thus, the effect of 
NANC contractile mechanisms was unopposed during field stimulation in preparations from the 
lovastatin-treated animals in part due to a deficiency in the interplay between cAMP and cGMP 
elevating agents supplemented with partial loss of cGMP effects. After combined treatment 
with lovastatin and farnesol, the normal NANC relaxation response was re-gained with an 
increase in tissue cGMP content in response to field stimulation. 
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Fig. 10. 
Fig. 10. Schematic diagram of the link between isoprenoid biosynthesis and mechanisms underlying NANC 
relaxation of the sphincter of Oddi. Inhibition of HMG-CoA by lovastatin decreases formation of non-
cholesterol mevalonate products such geranyl-PP and farnesyl-PP important in protein prenylation, a process that 
plays a key role of membrane particulation of G proteins. Thus, inhibition by lovastatin of HMG-CoA reductase 
results in a deficiency in G protein-dependent signal transduction pathways such as cAMP formation and 
activation of potassium channels. 
Our data seem to support the assumption that a deficiency in the synthesis of non-
cholesterol mevalonate products induced by either experimental hypercholesterolaemia or 
pharmacological inhibition of HMG-CoA reductase, the key enzyme of cholesterol 
biosynthesis impairs NANC relaxation of the sphincter of Oddi. Farnesol supplementation 
however, restored the relaxation response in both cases (67). 
Recent studies have suggested that non-cholesterol mevalonate products are 
implicated in the control of vascular tone and blood pressure (34, 68). Since NANC relaxation 
is a pre-requisite for normal delivery of bile into the duodenum, a mechanism vulnerable to 
lovastatin, it is strongly suggested that non-sterol mevalonate-derived metabolites 
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significantly contribute to the control of extrahepatic biliary tract motility as well (67). This is 
supported by the fact that farnesol, the natural dephosphorylated form of farnesyl 
pyrophosphate that participates in protein farnesylation recaptures the normal NANC 
relaxation function deteriorated by either hypercholesterolaemia (67) or HMG-CoA reductase 
inhibition. In certain clinical cases, however, a one-month treatment with a low lovastatin 
dose (20 mg/kg in the evening), alleviated post-prandial right upper quadrant pain and 
improved the responsiveness to amylnitrite to enhance transpapillary bile flow as confirmed 
by results from hepatobiliary scintigraphy (32). The virtual contradiction may at least in part 
be explained by the difference in the degree of HMG-CoA reductase inhibition in different 
tissues in different species and that lovastatin may mask the effect of hypercholesterolaemia 
that deteriorates the relaxation function of the sphincter of Oddi by itself. 
Of course, based on the present results, it is not possible to define the precise 
mechanism of action of farnesol to provide a beneficial influence on nitrergic relaxation of the 
sphincter of Oddi from either hypercholesterolaemic or with HMG-CoA reductase inhibitor 
treated animals. 
Beyond providing further evidence that non-sterol mevalonate products participate in 
widespread physiological regulatory mechanisms including sphincter of Oddi function, the 
results call attention to the non-lipid lowering effect of HMG-CoA reductase inhibitors which 
should be taken into account especially with long term use of these drugs. 
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